-
Congratulations to the 3 experts of the China Pharmaceutical Innovation Promotion Association for being elected as academicians of the two academies
Time of Update: 2021-12-06
, Representative of the 11th, 12th, and 13th National People's Congress, currently Director of the State Key Laboratory of New Technology of Chinese Medicine Pharmaceutical Process, Director of the National and Local Joint Engineering Research Center for Intelligent Manufacturing of Chinese Patent Medicines, concurrently serving as an executive member of the National Pharmacopoeia Commission, vice president of the Chinese Society of Chinese Medicine, and an executive director of the Chinese Society of Integrative Medicine .
-
The 70 billion children's medicine market was ignited, and Hengrui and Kangyuan kept rising!
Time of Update: 2021-12-06
Table 1: The situation of children's medicines in the list of essential medicines of the 2018 edition Source: Mi Nei. com, China's public medical institutions terminal competition pattern Note: * is a newly-added product, and the sales volume is less than 100 million yuan, replaced by # Figure 1: The subcategories involved in 22 children's medicines The 2018 edition of the basic medicine catalog involves 22 children’s medicines, and 5 chemical medicines are distributed in 4 sub-categories.
-
Domestic PD-1 goes to sea, Livzon Group and Bright Peak reach overseas authorized cooperation
Time of Update: 2021-12-06
Fredrik Wiklund, President and CEO of BPTx, said: “We are very pleased to obtain the license of Livzon’s anti-PD-1 monoclonal antibody LZM009 to extensively develop PD-1 targeted immune cytokines through the use of our proprietary platform technology .
-
Kelun Botai: The third domestically produced PD-L1 monoclonal antibody reported for listing
Time of Update: 2021-12-06
Tetley monoclonal antibody injection PD-L1 monoclonal antibody injection Corning Jerry Enwo Li monoclonal antibody injection cornerstone Pharmaceutical Shu Geli monoclonal antibody injection , paragraph 3 of the declaration listed domestic PD-L1 monoclonal antibody (Domestic PD-1/PD-L1 monoclonal antibodies that have been marketed/declared for listing: Sorting out: Target Society) Today, the competition of PD-1 monoclonal antibody has become fierce.
-
Designed to cure diabetes, CRISPR-edited cell replacement therapy enters the clinic
Time of Update: 2021-12-06
On November 16, 2021, ViaCyte and CRISPR Therapeutics jointly announced that Health Canada has approved a clinical trial application (CTA) for CRISPR gene-edited stem cell-derived therapy VCTX210 for the treatment of type 1 diabetes (T1D) .
-
The latest list of the world's top 1,000 pharmaceutical companies!
Time of Update: 2021-12-06
Pien Tze Huang rises to 16 places in a row, and the market value of Ameike surpasses Yunnan Baiyao In general, the ranking of Chinese medicine companies has slightly improved among global pharmaceutical companies .
-
Just now, GlaxoSmithKline "Mepolizumab" was approved in China
Time of Update: 2021-12-06
Suitable for adult patients with eosinophilic granulomatous polyangiitis Screenshot source: CDE official website According to the clinical trial data of the drug approved in the United States for the treatment of this indication, compared with placebo , patients receiving mepolizumab have a significantly longer accumulation time for remission .
-
Notice on Publicly Soliciting Opinions on the "Guiding Principles of Statistics for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments)"
Time of Update: 2021-12-06
pdf 3 "Guiding Principles of Statistics for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments)" feedback form for soliciting opinions.
docx3 "Guiding Principles of Statistics for Clinical Research of Rare Disease Drugs (Draft for Solicitation of Comments)" feedback form for soliciting opinions.
-
Under the froth of the "Great Innovation Era", the "involution" of biological products has become fierce
Time of Update: 2021-12-06
This article focuses on the analysis of the clinical trial information of biological products registered in the "Annual Report on the Status of Clinical Trials of New Drug Registration in China (2020)" .
-
Pfizer and the U.S. government sign a large single treatment for the new crown oral drug for US$529
Time of Update: 2021-12-06
According to the Financial Associated Press (Shanghai, editor Shi Zhengcheng), before the market on Thursday, local time, Pfizer announced that it has signed a purchase order for the new crown oral drug Paxlovid with the US government, which also means that the drug's price for developed countries is also synchronized.
-
This pharmaceutical company is amazing!
Time of Update: 2021-12-06
Recently, Simcere Pharmaceuticals announced that it has reached a project cooperation with Shanghai Institute of Medicine and others on the global development, production and commercialization of the new coronavirus drug candidate SIM0417 series .
-
Pfizer submitted an emergency authorization application for oral new crown drugs and agreed to other companies' production. CDMO will win Calaiying?
Time of Update: 2021-12-06
If authorized or approved, this oral drug is particularly suitable for low-income and middle-income countries, and can play a key role in saving lives and contribute to the global fight against the new crown epidemic," MPP Executive Director Charles Gore (Charles Gore) added, "We will work with generic drug companies to make the combination therapy of PF-07321332 and the HIV drug ritonavir, which can provide patients with sufficient supply .
-
Development Trends of China's Innovative Tumor Drugs
Time of Update: 2021-12-05
Attracted by the huge market pie, more and more innovative pharmaceutical companies have also poured into the field of anti-cancer drugs, which has created a continuous increase in the number of anti-cancer drugs in China .
-
Another province released the "dual channel" catalog!
Time of Update: 2021-12-05
According to the plan of the National Medical Insurance Administration, before the end of October this year, all provinces must determine the list of drugs that are included in the "dual-channel" management of the province and announce it to the public .
-
PD-L1 monoclonal antibody white fever: The third domestically-made PD-L1 monoclonal antibody has been reported for marketing, and 30+ models have been reported for clinical use
Time of Update: 2021-12-05
Tetley monoclonal antibody injection PD-L1 monoclonal antibody injection Corning Jerry Enwo Li monoclonal antibody injection cornerstone Pharmaceutical Shu Geli monoclonal antibody injection , paragraph 3 of the declaration listed domestic PD-L1 monoclonal antibody (Domestic PD-1/PD-L1 monoclonal antibodies that have been marketed/declared for listing: Sorting out: Target Society) Today, the competition of PD-1 monoclonal antibody has become fierce.
-
The impact of centralized procurement, new opportunities for the original research pharmaceutical companies are here
Time of Update: 2021-12-05
The sales decline of the selected original research is much greater than that of the unselected original research Figure 8-12 respectively shows the changes in the overall market sales of the original research related to the 1-2 batches of centralized procurement regulations of these 5 companies .
-
Ever threatened to lay off doctors and lose more than one billion years in a row. Medical artificial intelligence is ready to abandon Beijing, Shanghai and Guangzhou?
Time of Update: 2021-12-05
Data shows that from 2019 to the first half of 2021, Sukun Technology has accumulated losses of more than 300 million yuan; although it is assumed that the loss of medical care in the first quarter of this year has shrunk to 17.
-
Notice of the Center for Drug Evaluation to improve the progress of the review and approval of APIs
Time of Update: 2021-12-05
In order to improve the transparency of drug review and approval, strengthen information disclosure and respond to social concerns .
Our center has further improved the function of querying the review and approval progress of APIs.
-
Redefine the automation of the entire sequencing process!
Time of Update: 2021-12-05
It is hoped that the launch of the AVENIO Edge System can help our laboratories enter the era of automation and intelligence in the entire sequencing process, and contribute to life science research, clinical transformation, and molecular research.
-
New Deals frequently come out, 6-picture analysis of the API market
Time of Update: 2021-12-05
171 patents will expire, so a large number of generic drugs will be launched in the next few years, and the demand for corresponding APIs will increase accordingly .
